Profil
Morgan Sheng is a Professor at the Massachusetts Institute of Technology.
He was previously an Independent Director at Prevail Therapeutics, Inc. from 2019 to 2021 and a Vice President-Neuroscience at Genentech, Inc. He holds a doctorate degree from Harvard University and the University of London, and an undergraduate degree from the University of Oxford.
Postes actifs de Morgan Sheng
| Sociétés | Poste | Début |
|---|---|---|
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Morgan Sheng
| Sociétés | Poste | Fin |
|---|---|---|
| PREVAIL THERAPEUTICS INC. | Directeur/Membre du Conseil | 22/01/2021 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | - |
Formation de Morgan Sheng
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prevail Therapeutics, Inc.
Prevail Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutics for neurodegenerative diseases | Health Technology |
















